![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety, Pharmacokinetics, and Antiviral Activity of Single Oral Doses of the HCV NS3 Protease Inhibitor GS-9256
|
|
|
Reported by Jules Levin
AASLD 2010 Nov 2 Boston
R Goldwater1, M DeMicco2, J Zong3, G Chittick3, G Yuen3, S West3, J Kagel3, A Bae3, H Mo3, D Oldach3, W Delaney3, and J Findlay3
1PAREXEL International, Baltimore, MD, 2Advanced Clinical Research Institute, Anaheim, CA, 3Gilead Sciences, Foster City, CA.
![](../images/110710/110710-1/rest-1.gif)
![](../images/110710/110710-1/con-2.gif)
![](../images/110710/110710-1/obj-3.gif)
![](../images/110710/110710-1/results-4.gif)
![](../images/110710/110710-1/study-5.gif)
![](../images/110710/110710-1/HCV-6.gif)
![](../images/110710/110710-1/para-7.gif)
![](../images/110710/110710-1/fig-8.gif)
![](../images/110710/110710-1/mut-9.gif)
![](../images/110710/110710-1/other-10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|